Search

Your search keyword '"Bright, John R."' showing total 17 results
Start Over Author "Bright, John R."
17 results on '"Bright, John R."'

2. Abstract PR005: Tracing the clonal dynamic of metastatic castration-resistant prostate cancer over immunotherapy using circulating tumor DNA

Author

Li, Chennan, primary, Baj, Anna, additional, Seo, Clara C. Y., additional, Terrigino, Nicholas T., additional, Bright, John R., additional, Hennigan, S. Thomas, additional, King, Isaiah M., additional, Wilkinson, Scott, additional, Trostel, Shana Y., additional, Figg, William D., additional, Dahut, William L., additional, Lee, Jung Min, additional, Takeda, David Y., additional, Karzai, Fatima, additional, and Sowalsky, Adam G., additional

Published
2024
Full Text
View/download PDF

3. A case report of multiple primary prostate tumors with differential drug sensitivity

Author

Wilkinson, Scott, Harmon, Stephanie A., Terrigino, Nicholas T., Karzai, Fatima, Pinto, Peter A., Madan, Ravi A., VanderWeele, David J., Lake, Ross, Atway, Rayann, Bright, John R., Carrabba, Nicole V., Trostel, Shana Y., Lis, Rosina T., Chun, Guinevere, Gulley, James L., Merino, Maria J., Choyke, Peter L., Ye, Huihui, Dahut, William L., Turkbey, Baris, and Sowalsky, Adam G.

Published
2020
Full Text
View/download PDF

4. Supplementary Figure from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

Author

Sowalsky, Adam G., primary, Figueiredo, Ines, primary, Lis, Rosina T., primary, Coleman, Ilsa, primary, Gurel, Bora, primary, Bogdan, Denisa, primary, Yuan, Wei, primary, Russo, Joshua W., primary, Bright, John R., primary, Whitlock, Nichelle C., primary, Trostel, Shana Y., primary, Ku, Anson T., primary, Patel, Radhika A., primary, True, Lawrence D., primary, Welti, Jonathan, primary, Jimenez-Vacas, Juan M., primary, Rodrigues, Daniel Nava, primary, Riisnaes, Ruth, primary, Neeb, Antje, primary, Sprenger, Cynthia T., primary, Swain, Amanda, primary, Wilkinson, Scott, primary, Karzai, Fatima, primary, Dahut, William L., primary, Balk, Steven P., primary, Corey, Eva, primary, Nelson, Peter S., primary, Haffner, Michael C., primary, Plymate, Stephen R., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Data from Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

Author

Sowalsky, Adam G., primary, Figueiredo, Ines, primary, Lis, Rosina T., primary, Coleman, Ilsa, primary, Gurel, Bora, primary, Bogdan, Denisa, primary, Yuan, Wei, primary, Russo, Joshua W., primary, Bright, John R., primary, Whitlock, Nichelle C., primary, Trostel, Shana Y., primary, Ku, Anson T., primary, Patel, Radhika A., primary, True, Lawrence D., primary, Welti, Jonathan, primary, Jimenez-Vacas, Juan M., primary, Rodrigues, Daniel Nava, primary, Riisnaes, Ruth, primary, Neeb, Antje, primary, Sprenger, Cynthia T., primary, Swain, Amanda, primary, Wilkinson, Scott, primary, Karzai, Fatima, primary, Dahut, William L., primary, Balk, Steven P., primary, Corey, Eva, primary, Nelson, Peter S., primary, Haffner, Michael C., primary, Plymate, Stephen R., primary, de Bono, Johann S., primary, and Sharp, Adam, primary

Published
2023
Full Text
View/download PDF

6. Prostate-Specific Membrane Antigen Is a Biomarker for Residual Disease following Neoadjuvant Intense Androgen Deprivation Therapy in Prostate Cancer

Author

Bright, John R., primary, Lis, Rosina T., additional, Ku, Anson T., additional, Terrigino, Nicholas T., additional, Whitlock, Nichelle C., additional, Trostel, Shana Y., additional, Carrabba, Nicole V., additional, Harmon, Stephanie A., additional, Turkbey, Baris, additional, Wilkinson, Scott, additional, and Sowalsky, Adam G., additional

Published
2022
Full Text
View/download PDF

7. Assessment of Androgen Receptor Splice Variant-7 as a Biomarker of Clinical Response in Castration-Sensitive Prostate Cancer

Author

Sowalsky, Adam G., primary, Figueiredo, Ines, additional, Lis, Rosina T., additional, Coleman, Ilsa, additional, Gurel, Bora, additional, Bogdan, Denisa, additional, Yuan, Wei, additional, Russo, Joshua W., additional, Bright, John R., additional, Whitlock, Nichelle C., additional, Trostel, Shana Y., additional, Ku, Anson T., additional, Patel, Radhika A., additional, True, Lawrence D., additional, Welti, Jonathan, additional, Jimenez-Vacas, Juan M., additional, Rodrigues, Daniel Nava, additional, Riisnaes, Ruth, additional, Neeb, Antje, additional, Sprenger, Cynthia T., additional, Swain, Amanda, additional, Wilkinson, Scott, additional, Karzai, Fatima, additional, Dahut, William L., additional, Balk, Steven P., additional, Corey, Eva, additional, Nelson, Peter S., additional, Haffner, Michael C., additional, Plymate, Stephen R., additional, de Bono, Johann S., additional, and Sharp, Adam, additional

Published
2022
Full Text
View/download PDF

8. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy

Author

Wilkinson, Scott, primary, Ye, Huihui, additional, Karzai, Fatima, additional, Harmon, Stephanie A., additional, Terrigino, Nicholas T., additional, VanderWeele, David J., additional, Bright, John R., additional, Atway, Rayann, additional, Trostel, Shana Y., additional, Carrabba, Nicole V., additional, Whitlock, Nichelle C., additional, Walker, Stephanie M., additional, Lis, Rosina T., additional, Abdul Sater, Houssein, additional, Capaldo, Brian J., additional, Madan, Ravi A., additional, Gulley, James L., additional, Chun, Guinevere, additional, Merino, Maria J., additional, Pinto, Peter A., additional, Salles, Daniela C., additional, Kaur, Harsimar B., additional, Lotan, Tamara L., additional, Venzon, David J., additional, Choyke, Peter L., additional, Turkbey, Baris, additional, Dahut, William L., additional, and Sowalsky, Adam G., additional

Published
2021
Full Text
View/download PDF

9. Prostate-specific membrane antigen is a biomarker for residual disease following neoadjuvant intense androgen deprivation therapy in prostate cancer

Author

Bright, John R., primary, Lis, Rosina T., additional, Ku, Anson T., additional, Terrigino, Nicholas T., additional, Trostel, Shana Y., additional, Carrabba, Nicole V., additional, Harmon, Stephanie A., additional, Turkbey, Baris, additional, Wilkinson, Scott, additional, and Sowalsky, Adam G., additional

Published
2021
Full Text
View/download PDF

10. Sequential Prostate Magnetic Resonance Imaging in Newly Diagnosed High-risk Prostate Cancer Treated with Neoadjuvant Enzalutamide is Predictive of Therapeutic Response

Author

Karzai, Fatima, primary, Walker, Stephanie M., additional, Wilkinson, Scott, additional, Madan, Ravi A., additional, Shih, Joanna H., additional, Merino, Maria J., additional, Harmon, Stephanie A., additional, VanderWeele, David J., additional, Cordes, Lisa M., additional, Carrabba, Nicole V., additional, Bright, John R., additional, Terrigino, Nicolas T., additional, Chun, Guinevere, additional, Bilusic, Marijo, additional, Couvillon, Anna, additional, Hankin, Amy, additional, Williams, Monique N., additional, Lis, Rosina T., additional, Ye, Huihui, additional, Choyke, Peter L., additional, Gulley, James L., additional, Sowalsky, Adam G., additional, Turkbey, Baris, additional, Pinto, Peter A., additional, and Dahut, William L., additional

Published
2021
Full Text
View/download PDF

11. Nascent prostate cancer heterogeneity drives evolution and resistance to intense hormonal therapy

Author

Wilkinson, Scott, primary, Ye, Huihui, additional, Karzai, Fatima, additional, Harmon, Stephanie A., additional, Terrigino, Nicholas T., additional, VanderWeele, David J., additional, Bright, John R., additional, Atway, Rayann, additional, Trostel, Shana Y., additional, Carrabba, Nicole V., additional, Whitlock, Nichelle C., additional, Walker, Stephanie M., additional, Lis, Rosina T., additional, Sater, Houssein A., additional, Capaldo, Brian J., additional, Madan, Ravi A., additional, Gulley, James L., additional, Chun, Guinevere, additional, Merino, Maria J., additional, Pinto, Peter A., additional, Salles, Daniela C., additional, Kaur, Harsimar B., additional, Lotan, Tamara L., additional, Venzon, David J., additional, Choyke, Peter L., additional, Turkbey, Baris, additional, Dahut, William L., additional, and Sowalsky, Adam G., additional

Published
2020
Full Text
View/download PDF

14. Solvent Selection for Lignin Value Prior to Pulping.

Author

Kwok, Thomas T., Bright, John R., Vora, Soor R., Chrisandina, Natasha J., Luettgen, Christopher O., Realff, Matthew J., and Bommarius, Andreas S.

Subjects
CHEMICAL processes, LIGNINS, LIGNOCELLULOSE, PULPING, FUNCTIONAL groups, CELLULOSE fibers, SOLVENTS, FEEDSTOCK
Abstract

Solvent selection guides are crucial in chemical process design and development. Lignin from lignocellulosic biomass is a potentially attractive feedstock for sustainable chemical feedstocks. One approach would use a solvent to recover lignin prior to the traditional pulping process to make cellulose fibers: lignin value prior to pulping (LVPP). A solvent selection methodology for LVPP is presented herein that may be expanded for any proposed solvent for this process. Four screening categories are elucidated, providing metrics for 30 solvents across multiple molecular functional groups. Through performance, hazards and environment, cost and availability, and process‐economics screens, the initial list of solvents is reduced to two top‐tier candidates, 1,6 hexamethylenediamine and diethanolamine. 1‐Methylpiperazine also emerged as a potential candidate. This solvent‐selection methodology streamlines experimentation and provides promising candidates for LVPP. In addition to creating a tailored solvent selection guide, valuable biomass pretreatment data that may be utilized in different renewable applications are also presented. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

17. Localized high-risk prostate cancer harbors an androgen receptor low subpopulation susceptible to HER2 inhibition.

Author

Wilkinson S, Ku AT, Lis RT, King IM, Low D, Trostel SY, Bright JR, Terrigino NT, Baj A, Fenimore JM, Li C, Vo B, Jansen CS, Ye H, Whitlock NC, Harmon SA, Carrabba NV, Atway R, Lake R, Kissick HT, Pinto PA, Choyke PL, Turkbey B, Dahut WL, Karzai F, and Sowalsky AG

Abstract

Patients diagnosed with localized high-risk prostate cancer have higher rates of recurrence, and the introduction of neoadjuvant intensive hormonal therapies seeks to treat occult micrometastatic disease by their addition to definitive treatment. Sufficient profiling of baseline disease has remained a challenge in enabling the in-depth assessment of phenotypes associated with exceptional vs. poor pathologic responses after treatment. In this study, we report comprehensive and integrative gene expression profiling of 37 locally advanced prostate tumors prior to six months of androgen deprivation therapy (ADT) plus the androgen receptor (AR) inhibitor enzalutamide prior to radical prostatectomy. A robust transcriptional program associated with HER2 activity was positively associated with poor outcome and opposed AR activity, even after adjusting for common genomic alterations in prostate cancer including PTEN loss and expression of the TMPRSS2:ERG fusion. Patients experiencing exceptional pathologic responses demonstrated lower levels of HER2 and phospho-HER2 by immunohistochemistry of biopsy tissues. The inverse correlation of AR and HER2 activity was found to be a universal feature of all aggressive prostate tumors, validated by transcriptional profiling an external cohort of 121 patients and immunostaining of tumors from 84 additional patients. Importantly, the AR activity-low, HER2 activity-high cells that resist ADT are a pre-existing subset of cells that can be targeted by HER2 inhibition alone or in combination with enzalutamide. In summary, we show that prostate tumors adopt an AR activity-low prior to antiandrogen exposure that can be exploited by treatment with HER2 inhibitors., Competing Interests: Competing interests H.Y. and R.T.L. perform consulting in an advisory role for Janssen Pharmaceuticals. A.G.S. reports that the National Cancer Institute (NCI) has a Cooperative Research and Development Agreement (CRADA) with Astellas. Resources are provided by this CRADA to the NCI. A.G.S. gets no personal funding from this CRADA but is the primary investigator of the CRADA. The remaining authors declare no conflicts of interest.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results